tbuckley/cabot-search huggingface dataset:
Financial Indigestion
Authors: J P Kassirer
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ -forming hydrogels for intratumoral administration
Authors: Jiangshan Wan, Shinan Geng, Hao Zhao, Xiaole Peng, Qing Zhou, Han Li, Ming He, Yanbing Zhao, Xiangliang Yang, Huibi Xu
Journal: Journal of Controlled Release (2016)
Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning
Authors: Jeffrey Duryea, Ruby Russell, Ellen M. Gravallese, Jonathan Kay, Roger Han, Bing Lu, Daniel H. Solomon
Journal: Arthritis & Rheumatology (2015)

Valid measurement of erosion volume in rheumatoid arthritis (RA) will facilitate the testing of treatments that may help to heal erosion. This study was undertaken to develop and validate a software method to measure erosion volume on computed tomography (CT) scans of the hand and wrist. Duplicate CT acquisitions of both hands of 5 patients with RA were evaluated using a semiautomated software tool to measure erosion volume in the entire hand and wrist and in each of 6 subregions. Reproducibility was quantified using the intraclass correlation coefficient (ICC), root mean square standard deviation (RMSSD), and coefficient of variation (CV), and the analysis was performed at the level of the hand (n = 10) and the subject (n = 5). The ICCs between 2 repositioned acquisitions were excellent, ranging from 0.97 to 1.00. At the hand level, the RMSSD was 15.6 mm(3) with a CV of 7.3%, and the CVs at the 6 regions ranged from 7.6% to 21.0%. At the subject level, the RMSSD was 31.2 mm(3) with a CV of 3.7%, and the CVs at the 6 regions ranged from 0.5% to 15.8%. We have developed a novel semiautomated software method to measure erosion volume on hand and wrist CT scans. The method is reproducible and can be used to detect changes in erosion volume. This will facilitate the testing of treatments intended to reduce erosion volume.
Studies on the Disappearance of the Mammary-Tumor Agent in Mice of Strains C3H and C
Authors: H B ANDERVONT
Journal: JNCI Journal of the National Cancer Institute (1949)

Studies on the Disappearance of the Mammary-Tumor Agent in Mice of Strains C3H and C Howard B. Andervont Howard B. Andervont National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 1, August 1949, Pages 201–214, https://doi.org/10.1093/jnci/10.1.201 Published: 01 August 1949 Article history Received: 16 June 1949 Published: 01 August 1949
AB0350 Change of Cerebrovascular Blood Flow in Rheumatology Patients Before and After Treatment of Rituximab: Table 1.
Authors: U. Uygar, G. Yildirim-Cetin, N. Atilla
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> Rituximab is a monoclonal antibody drug used in malignancies and autoimmune diseases. Rituximab used for improving the symptoms and preventing rheumatic disease. We examined the effects of rituximab treatment on the cerebral blood flow velocity with transcranial Doppler ultrasonography (TCD) in rheumatic patients. <h3>Methods</h3> 20-65 aged 7 patients (2 patients with secondary interstitial lung involvement to rheumatoid arthritis, 3 patients with systemic lupus erythematosus and lupus nephritis, 2 patients with scleroderma and secondary interstitial lung disease) who receive rituximab treatment due to rheumatic diseases were included the study. Patients were evaluated before rituximab treatment and after 6 months. Values of bilateral middle cerebral artery (MCA) peak-systolic,end-diastolic and mean blood flow velocity, Gosling pulsatility index values and Pourcelot resistance index value were recorded with TCD by a neurosonologist blinded to patients. The obtained values were compared with each other. <h3>Results</h3> 1 patient was male and 6 patients were female. The mean age was found 52.3±4.7. TCD values were compared before and after treatment with rituximab. After treatment the peak-systolic, end-diastolic and mean blood flow velocity were significantly lower. <h3>Conclusions</h3> Inflammation has an important role in the pathogenesis and prognosis of atherosclerosis. In these patients, particularly IL-6, TNF-alpha and CRP as inflammatory markers are found in high levels. Significantly increased cerebral blood flow velocity can be caused by atherosclerosis mechanism in this patients before treatment. In the sixth month After Rituximab treatment, decreasing high blood flow velocity was thought to be due to subdued inflammation. <h3>Disclosure of Interest</h3> None declared
AB0443 Selective Immunomodulators of FC-Gamma Receptors (SIFS) to Inhibit Autoantibody-Mediated Pathology
Authors: C.J. Bosques, J. Lansing, D. Ortiz, L. Rutitzky, N. Washburn, N. Bhatnagar, E. Kurtagic, A. Choudhury, T. Prod'homme, B. Schultes, S. Roy, G.V. Kaundinya, A.M. Manning
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Interaction of autoantibodies and immune complexes with Fcγ-receptors on leukocytes can lead to detrimental inflammatory events in autoimmune diseases including inflammatory synovitis. Modulation of Fcγ-receptor-mediated leukocyte activation could serve as an attractive strategy to limit acute exacerbations and recurrent disease symptoms in rheumatoid arthritis and multiple disease settings. <h3>Objectives</h3> To develop best-in-class modulators of Fcγ-receptors and assess their activity in antibody-mediated pathogenic mechanisms active in autoimmune diseases. <h3>Methods</h3> We designed a panel of novel recombinant multimeric-Fc drug candidates to modulate the activity of low affinity Fcγ-receptors. A comprehensive panel of physicochemical and pharmacological assays including <i>in-vivo</i> models of Immune Thrombocytopenic Purpura (ITP) and synovitis (Collagen Antibody-Induced Arthritis; CAIA) was used to select the candidate with optimal drug properties. <h3>Results</h3> An optimal multimeric-Fc drug candidate was selected for development based on its attractive physicochemical and biological properties. This candidate demonstrated more than 40 fold higher potency than Intravenous Immunoglobulins (IVIg) in multiple <i>in-vivo</i> models of autoimmune diseases and more than 100 fold potency in different assays of immune cell activation. <h3>Conclusions</h3> Selective Immunomodulators of Fcγ-receptors (SIFs) are effective inhibitors of various antibody-mediated pathogenic mechanisms. These novel agents may prove to have therapeutic value in the treatment of autoimmune diseases. <h3>Disclosure of Interest</h3> None declared
THE STORY OF DMSO
Authors: O E AUFRANC, W N JONES, W G STEWART
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAT0586 Ultrasonographic Signs Of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients who are Treated to Target
Authors: M. van der Ven, D. Ten Cate, A. Gerards, H. Jacobs, N. Swen, M. de Jager, N. Basoski, C. Haagsma, M. Hazes, J. Luime
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The feet are often involved in rheumatoid arthritis (RA), but physical examination of the metatarsophalangeal (MTP) joints to detect arthritis is always challenging especially in case of obesity, oedema and malalignment. Ultrasound (US) has proven to be more sensitive than physical examination to detect (subclinical) synovitis in the MTP joints. <h3>Objectives</h3> (i) To determine the frequency of subclinical synovitis in the MTP joints by US among patients in DAS28 remission or LDA, and (ii) to assess discordance between the evolution of US arthritis in the feet and DAS28 over time in newly diagnosed RA patients who are treated to target. <h3>Methods</h3> A multicentre cohort of newly diagnosed RA patients was followed prospectively for one year. Patients were treatment naïve for synthetic DMARDs, biological DMARDs and glucocorticoids, and symptom duration was less than one year. All patients were treated to target with regular visits. Demographics, clinical (SJC28, TJC28) and laboratory (ESR, RF, ACCP) parameters were recorded at each visit. US examination of the dorsal aspect of MTP2-5 joints was performed at baseline, three months and one year. Images were scored on greyscale (GS; 0-3) and power Doppler (PD; 0-3). A US positive MTP joint was defined by GS&gt;1 and/or PD&gt;0. Simple descriptive statistics were used and longitudinal course of both DAS28 and number of US positive MTP joints were plotted for each patient. Discordance of course was defined as crossing of slopes. <h3>Results</h3> At baseline, 174 patients were included of whom 159 completed one year follow-up. At baseline, 109 (73%) patients had at least one US positive MTP joint. Overall, mean (SD) DAS28 decreased from 4.9 (1.3) at baseline to 2.3 (1.2) at one year, while the number of US positive MTP joints decreased from median (interquartile range) 1 (0-4) at baseline to 0 (0-0) at one year. Discordance in longitudinal course of DAS28 and US positive MTP joints over one year was seen in 9 patients (6%). After one year of follow-up, 98 (62%) patients were in DAS28 remission (DAS28&lt;2.6) of whom 23 (23%) still had at least one US positive MTP joint. Twenty-nine patients had low disease activity (DAS28≤3.2) of whom 7 (24%) had at least one US positive MTP joint. <h3>Conclusions</h3> Most patients (94%) improved both in DAS28 score and number of US positive MTP joints during follow-up. However, 23% of the early RA patients in DAS28 remission still had subclinical synovitis on US in at least one MTP joint at one year. Monitoring of MTP joints by US and subsequent steering of treatment might be considered to prevent for example progressive radiological damage. <h3>Disclosure of Interest</h3> None declared
Report of Two Cases of Identical Primary Tumors Involving Spinal Nerve Roots and Meninges in Strain NHO Mice
Authors: Harold L. Stewart, Henry S. Kaplan, James G. Bennett
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article Report of Two Cases of Identical Primary Tumors Involving Spinal Nerve Roots and Meninges in Strain NHO Mice Get access Harold L. Stewart, Harold L. Stewart chief, pathology section Search for other works by this author on: Oxford Academic PubMed Google Scholar Henry S. Kaplan, Henry S. Kaplan medical officer in radiology, biophysics section Search for other works by this author on: Oxford Academic PubMed Google Scholar James G. Bennett James G. Bennett pathologist National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda 14, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 1, August 1950, Pages 177–197, https://doi.org/10.1093/jnci/11.1.177 Published: 01 August 1950 Article history Published: 01 August 1950 Received: 23 August 1950
Comprehensive Mutational Profiling In Myelodysplastic Syndromes Treated With Decitabine and Tretinoin
Authors: Alan H. Shih, Sean M. Devlin, Emily K. Dolezal, Kristina M. Knapp, Kai Wang, Eric M. Sanford, Tim Brennan, Roman Yelensky, Michelle Nahas, Geoff A Otto, Doron Lipson, Philip J Stephens, Vincent Miller, Marcel R.M. van den Brink, Ross L. Levine, Stephen Nimer, Virginia M. Klimek
Journal: Blood (2013)
PET/CT in a Patient Diagnosed With Dandy-Walker Syndrome
Authors: Jose R. Infante, Lucia Garcia, Juan I. Rayo, Justo Serrano, Maria L. Dominguez, Manuel Moreno
Journal: Clinical Nuclear Medicine (2015)

The Dandy-Walker syndrome (DWS) is a rare congenital posterior fossa malformation characterized by aplasia or hypoplasia of the cerebellar vermis, cystic dilatation of the fourth ventricle, and enlargement of the posterior fossa. We present a 52-year-old Caucasian man diagnosed with gastrointestinal stromal tumor and submitted to 18F-FDG PET/CT as a staging procedure. The patient was previously diagnosed with DWS in brain CT scan. PET/CT images revealed an ametabolic large cyst in the posterior fossa and hypoplasia of cerebellar vermis. The case is presented with the aim to show the appearance of this syndrome on PET/CT study.
Role of radiotherapy in neuroblastoma.
Authors: G J D'Angio, K K Matthay, A E Evans
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.11.2076 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1941067 Role of radiotherapy in neuroblastoma. G J D'AngioxG J D'AngioSearch for articles by this author , K K MatthayxK K MatthaySearch for articles by this author , A E EvansxA E EvansSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.11.2076 PDF "Role of radiotherapy in neuroblastoma.." Journal of Clinical Oncology, 9(11), pp. 2076–2077© 1991 by American Society of Clinical Oncology
OP0173 Inspiratory Muscle Training as a Method for Improving Aerobic Capacity and Pulmonary Function in Patients with Ankylosing Spondylitis: A Randomized Controlled Study
Authors: R.G. Dragoi, E.C. Amaricai, M. Dragoi, H. Popoviciu, C. Avram
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Pulmonary involvement in AS patients varies depending on the diagnostic method applied, its frequency beeing reported to be between 20% and 57% using spirometry, and between 40% and 80% in studies in which high resolution computed tomography was applied. Patients with AS have reduced pulmonary muscle strength and endurance. <h3>Objectives</h3> To evaluate the impact of inspiratory muscle training (IMT) on aerobic capacity and pulmonary function in patients with AS. <h3>Methods</h3> Fifty-four AS patients (mean age: 47.8±6.8 years old, all males) were randomized into either conventional rehabilitation exercise training associated with IMT, or to a conventional rehabilitation exercise training group only. All patients were assessed before and after the rehabilitation program, with respect to resting pulmonary function test (forced vital capacity - FVC, forced expiration volume in one second - FEV1), and cardiopulmonary exercise test (peak oxygen uptake - VO<sub>2</sub>peak, metabolic equivalents for oxygen – VE/VO<sub>2</sub> and carbon dioxide - VE/VCO<sub>2</sub>). The IMT sessions were performed using a real time computer assisted device (Trainair, Project Electronics Limited, United Kingdom) and took place three times a week for a period of 8 weeks. Each IMT session was individualized by evaluating the maximum inspiratory pressure that can be maintained by the patient throughout the inspiratory phase (SMIP) and was performed at 80-85% of SMIP. <h3>Results</h3> The two groups were homogenous in terms of pulmonary function and physical performances, as we found no statistical significant differences at the beginning of the study.There were significant increases in in followed parameters after rehabilitation programme in Group 1. Small improvements can be observed in pulmonary function and cardiopulmonary exercise test parameters of Group 2, but without reaching the statistical significance. <h3>Conclusions</h3> AS patients who performed 8 weeks of IMT associated to conventional exercise training had an increased chest expansion, a better aerobic capacity, resting pulmonary function and ventilatory efficiency than those who performed conventional exercise training only. IMT is a feasible treatment option in patients with pulmonary dysfunction due to AS. <h3>Disclosure of Interest</h3> None declared
The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder
Authors: D H Avery, T B Osgood, D M Ishiki, L G Wilson, M Kenny, D L Dunner
Journal: American Journal of Psychiatry (1985)

The authors administered the dexamethasone suppression test (DST) to outpatients, who were free from psychoactive drugs for at least 10 days before the test, with primary affective disorder (N = 60), generalized anxiety disorder (N = 26), panic disorder (N = 22), and agoraphobia with panic attacks (N = 13). With a cortisol value of 5 micrograms/dl considered nonsuppression, there were no significant differences in dexamethasone nonsuppression rates among the diagnostic groups. Scores on the Hamilton Rating Scale for Depression and a melancholia subscale were significantly higher in the depressed group than in the anxiety disorder group. The findings raise questions concerning the specificity of the DST for primary affective disorder in relationship to anxiety disorders.
DDEL-09QUANTIFICATION OF TRANSIENT BLOOD BRAIN BARRIER DISRUPTION FOLLOWING THE SYSTEMIC ADMINISTRATION OF REGADENOSON
Authors: Sadhana Jackson, Richard George, Sachin Gujar, Stuart Grossman
Journal: Neuro-Oncology (2015)

BACKGROUND: The blood brain barrier (BBB) makes it difficult for oral or intravenous chemotherapy to achieve therapeutic concentrations in brain parenchyma. Regadenoson is an adenosine receptor agonist which transiently disrupts the BBB, allowing systemically administered high molecular weight dextran (MW 70kD) to enter normal rodent brain. Our recent studies with this compound suggest that temozolomide concentrations in rodent brain are also increased by regadenoson. This FDA approved agent is used routinely for cardiac stress tests in patients unable to exercise along with visipaque and cardiac computed tomography (CT) imaging. Visipaque (MW 1550) typically only enters brain where there is significant disruption of the BBB. This study is being conducted to determine if regadenoson will allow more contrast to enter normal human brain. METHODS: Patients without known intracranial disease who were undergoing clinically indicated pharmacologic cardiac stress tests (visipaque with cardiac CT followed by visipaque with regadenoson and cardiac CT) were eligible. This IRB approved study only added brain CT pre- and post-regadenoson. Contrast delivery was measured in hounsfield units (HU), at the level of the basal ganglia, within the cortex, deep gray and white matter. A total of 27 patients are required to assist in comparison analysis of regional contrast uptake. A matched-pairs t-test was performed to determine if the difference was significant. RESULTS: Five of the 27 patients have been accrued and analyzed. There was no difference in contrast following visipaque alone and visipaque with regadenoson (29.3HU vs 30.2HU respectively, P = 0.06). CONCLUSION: Early results from this ongoing study suggest that even accounting for the additional visipaque dose there is a trend towards increased contrast enhancement following regadenoson administration in patients with presumably normal brains. Transient disruption of the BBB to facilitate drug entry using an FDA approved agent could be of significant importance to the field of neuro-oncology.
Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial
Authors: F. Quenet, B. Nordlinger, M. Rivoire, J. R. Delpero, G. Portier, D. Mery-Mignard, E. Magherini, S. Payrard, M. Ychou
Journal: Journal of Clinical Oncology (2004)

3613 Background: 5 year-survival after LMCRC resection is 30–35%. Folfiri and Folfox are standard regimens in MCRC. The triple combination Folfirinox as induction CT could improve tumor shrinkage and therefore could allow resection of LM in unresectable patients (pts). Methods: Based on a multidisciplinary consensus, unresectability is defined as follows: LM in right or left lobe in contact of controlateral liver pedicle; LM in contact of veina cava or involving 2 hepatic veins and in contact with the third; liver remaining mass less than 25–30% of functional liver; no initial forseen optimal resection, but susceptible to become resectable after shrinkage. Biweekly 48h-cycles (Cy): L-OHP 85 mg/m2, CPT-11 180 mg/m2, LV5FU were administered. An Independent Committee (IC) reviewed pts eligibility and RR. The primary endpoint was resectability R0 defined as R0= margin≥2mm, R1=margin<2mm, Ra= resection + either cryosurgery or radiofrequency. Results: Among 34 pts included, 25 were eligible as per IC. To date, 24 pts out of 25 were assessable for primary endpoint. Median age=57y [39–69], M/F=15/10, PS 0/1=17/8, metachronous LM=12 & synchronous LM=13. After a median number of 6 Cy [4–10] before surgery, the overall RR was 72% (CR=1, PR=17, MR=3, SD=1). Pathological status after surgery was: R0=9, R1=5, Ra=6. 2 pts had cryosurgery only and 2 pts were not operated upon. Thus 22 pts had complete local treatment and 14 pts could undergo surgical resection R0-R1. Post-surgical complication =2 biliary fistula, 2 infections leading to hospitalization were reported. After resection, the same CT was pursued in adjuvant setting till 12 Cy in 11 pts. Conclusions: In this population who initially could not undergo optimal resection, 37.5% of assessable pts underwent R0 resection and 91.7% could receive complete local treatment with resection and / or ablation procedures after active CT. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Laboratoire Aventis Laboratoire Aventis